Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients with paroxysmal atrial fibrillation (AF) as the company looks to ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant strides in recent years, positioning itself as a frontrunner in the industry.

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The long-term prospects of the WATCHMAN devices are also encouraging. Meanwhile, the adverse macroeconomic impacts as well as currency fluctuations pose a concern for Boston Scientific’s operations.

Ranked by Total sq. ft. managed in Mass. Boston, MA (January 15, 2024) – Wingate Multifamily, LLC, an affiliate of Wingate Companies of Newton… Strong Harbor Consulting, headquartered in ...

BSX develops, manufactures, and markets medical devices. The company primarily ... But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp ...

Credit: Shutterstock / Good dreams – Studio US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients with paroxysmal atrial ...